Tags : StemoniX

PharmaShots Weekly Snapshot (December 02-06, 2019)

Tuba Khan December 9, 2019

1. Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major […]readmore

Pharma

StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting

Tuba Khan December 3, 2019

Shots: Joint Venture will combine StemoniX’s human microOrgan platform with Atomwise’s AI technology to allow the rapid discovery and development of novel therapies, initially targeting Rett syndrome Atomwise will utilize […]readmore

Tags : StemoniX

PharmaShots Weekly Snapshot (December 02-06, 2019)

StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : StemoniX

PharmaShots Weekly Snapshot (December 02-06, 2019)

StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company